Holen Sie sich die Stockscreener-App
41.35
0.29%
0.12
Handel nachbörslich:
41.35
Schlusskurs vom Vortag:
$41.23
Offen:
$41.23
24-Stunden-Volumen:
646.73K
Relative Volume:
0.80
Marktkapitalisierung:
$2.02B
Einnahmen:
$140.49M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-15.01
EPS:
-2.7551
Netto-Cashflow:
$-175.90M
1W Leistung:
-4.39%
1M Leistung:
-10.81%
6M Leistung:
+128.20%
1J Leistung:
+139.57%
1-Tages-Spanne:
$40.65
$41.78
1-Wochen-Bereich:
$39.72
$44.08
52-Wochen-Spanne:
$15.86
$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
41.35 | 2.02B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - uk.finance.yahoo.com
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base - Yahoo Finance
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
UroGen Pharma (URGN) Stock Looks About Right As Sales Catch Up - simplywall.st
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions? - Insider Monkey
URGN Stock Price, Quote & Chart - ChartMill
UroGen Pharma (URGN) Stock May Still Trade At A Discount To Sales - simplywall.st
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction By Investing.com - Investing.com India
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction - Investing.com
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com Nigeria
UroGen Pharma general counsel sells $64,618 in shares - Investing.com India
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale - Kalkine Media
UroGen at Wells Fargo conference: launch gains and pipeline widen By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com Canada
Tyra Biosciences Shares Tumble 22% as Bladder Cancer Drug Misses Efficacy Benchmark - finance.biggo.com
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding - Stock Titan
UroGen Pharma advances with strong Zusduri sales and promising URGN-103 approval ahead - Pluang
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Manipulation Risk - careplusvn.com
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - Sahm
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet - Yahoo Finance
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):